| Literature DB >> 34053637 |
Shailja C Shah1, Richard M Peek2.
Abstract
Gastric cancer is the fifth most common cause of cancer and the third leading cause of cancer-related deaths globally. The number of gastric cancer-related deaths is only projected to increase, attributable primarily to the expanding aging population. Prevention is a mainstay of gastric cancer control programs, particularly in the absence of accurate, noninvasive modalities for screening and early detection, and the absence of an infrastructure for this purpose in the majority of countries worldwide. Herein, we discuss the evidence for several chemopreventive agents, along with putative mechanisms. There remains a clear, unmet need for primary chemoprevention trials for gastric cancer. Published by Elsevier Inc.Entities:
Keywords: Aspirin; Chemoprevention; Gastric neoplasm; Helicobacter pylori; Nonsteroidal anti-inflammatory drugs
Mesh:
Year: 2021 PMID: 34053637 PMCID: PMC8711598 DOI: 10.1016/j.giec.2021.03.006
Source DB: PubMed Journal: Gastrointest Endosc Clin N Am ISSN: 1052-5157